Biosimilar Red Tape Elimination Act
- Bill Number
- S. 1954
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2026-06-17: Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
- Last Updated
- 2026-06-26T20:02:16Z
AI-Generated Summary
Purpose
The Biosimilar Red Tape Elimination Act aims to streamline the approval process for biosimilar biological products (medicines similar to existing biologic drugs) by automatically deeming them interchangeable with their reference products, reducing regulatory hurdles and promoting faster market access to lower-cost alternatives.
Key Provisions
- Automatic Interchangeability: Biosimilars approved under Section 351(k) of the Public Health Service Act are automatically considered interchangeable with the reference product (the original biologic drug) upon approval, unless an existing exclusivity period (a limited time of market protection) applies to another product using the same reference.
- Transition Rules:
- For biosimilars approved on or after a "transition date" (60 days after the bill's enactment), interchangeability is granted immediately at approval.
- For biosimilars approved before the transition date, it is granted on the transition date.
- Existing exclusivity periods for first interchangeable biosimilars remain in effect until they expire.
- Application Requirements: Simplifies the information needed in biosimilar applications to focus on demonstrating biosimilarity (that the product is highly similar to the reference product with no clinically meaningful differences), removing separate interchangeability demonstrations.
- Guidance Updates: The Secretary of Health and Human Services (through the FDA) must update or revoke existing guidance on interchangeability within 18 months and issue new guidance on biosimilar approvals, focusing on data for biosimilarity determinations.
- Conforming Changes: Updates related laws to remove references to separate interchangeability standards, ensuring consistency across statutes like the Federal Food, Drug, and Cosmetic Act.
Significant Changes to Existing Law
- Removes Interchangeability Standards: Under current law (from the Biologics Price Competition and Innovation Act of 2009), biosimilars must meet strict criteria to prove interchangeability, such as switching studies showing no harm to patients. This bill eliminates those requirements, replacing them with automatic deeming upon biosimilar approval.
- Preserves Exclusivity: Maintains market protections for the first interchangeable biosimilar (up to 1 year of exclusivity), but applies it only to products approved before the bill's enactment.
- Simplifies Definitions and Processes: Redesignates and streamlines subsections in Section 351(k), removes pediatric assessment exceptions tied to interchangeability, and adjusts user fee provisions to exclude interchangeability supplements.
Potential Impacts
- On Government Agencies: The FDA will face reduced review burdens for interchangeability but must update guidance quickly, potentially speeding up approvals while ensuring biosimilarity standards are met.
- On Citizens: Patients could benefit from quicker access to cheaper biosimilars, lowering drug costs and improving affordability for treatments like insulin or cancer therapies; however, it may raise questions about automatic substitution at pharmacies without proven switching safety.
- On International Relations: Minimal direct impact, though it could influence global biosimilar markets by making U.S. approvals more attractive for international manufacturers, potentially affecting trade in pharmaceuticals.
- Broader Effects: Likely increases competition in the biologics market (valued at hundreds of billions), reducing prices by 20-30% for biosimilars, but could shorten revenue periods for original drug makers.
Main Stakeholders Affected
- Biosimilar Manufacturers: Gain easier entry to the market with automatic interchangeability, encouraging investment and innovation in affordable alternatives.
- Reference Product (Brand) Manufacturers: Face shorter exclusivity periods and increased competition, potentially reducing profits from original biologics.
- FDA and Regulators: Must adapt processes and guidance, with streamlined reviews but preserved safety focus on biosimilarity.
- Patients and Healthcare Providers: Benefit from cost savings and easier pharmacy substitutions; providers may need to adjust prescribing habits.
- Pharmacies and Payers (e.g., Insurers): Easier to substitute interchangeable biosimilars, lowering costs for health plans and consumers.
Notable Legal, Constitutional, or Political Implications
- Legal: Shifts regulatory burden from proving interchangeability to biosimilarity, potentially reducing litigation over approval standards but inviting challenges if safety issues arise post-approval. Aligns with administrative law by directing FDA guidance updates without mandating rulemaking.
- Constitutional: No direct implications, as it involves congressional authority over interstate commerce and public health under the Commerce Clause.
- Political: Bipartisan support (introduced by Sens. Lee, Lujan, Paul, and Hassan) reflects efforts to cut regulatory "red tape" and lower drug prices, aligning with broader debates on healthcare affordability and innovation incentives; could face opposition from brand-name pharma lobbies concerned about weakened protections.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (5)
Sen. Luján, Ben Ray [D-NM], Sen. Paul, Rand [R-KY], Sen. Hassan, Margaret Wood [D-NH], Sen. Schmitt, Eric [R-MO], Sen. Ossoff, Jon [D-GA]
Recent Actions
- 2026-06-17: Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
- 2025-06-04: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- 2025-06-04: Introduced in Senate
Bill Versions
- Biosimilar Red Tape Elimination Act — issued 2025-06-04 — PDF (9 pages)